Atrium Therapeutics, Inc. (RNA)
| Market Cap | 137.70M |
| Revenue (ttm) | 35.84M +228.9% |
| Net Income | -65.99M |
| EPS | -3.86 |
| Shares Out | 17.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,366 |
| Open | 8.20 |
| Previous Close | 8.20 |
| Day's Range | 7.98 - 8.23 |
| 52-Week Range | 7.49 - 16.77 |
| Beta | 0.93 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+185.71%) |
| Earnings Date | Aug 13, 2026 |
About RNA
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license a... [Read more]
Financial Performance
In 2025, Atrium Therapeutics's revenue was $18.62 million, an increase of 70.85% compared to the previous year's $10.90 million. Losses were -$49.50 million, 97.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 185.71% from the latest price.
News
Atrium Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Atrium Therapeutics (RNA) with a Buy rating and $15 price target The company aims to extend targeted RNA delivery from skeletal muscle…
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment In...
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a val...
Atrium Therapeutics announces $50M private placement
Atrium Therapeutics (RNA) announced that it has entered into a securities purchase agreement with a group of institutional investors for a private placement financing. The private placement is expecte...
Atrium Therapeutics Announces $50 Million Private Placement
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics t...
Atrium Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today...
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Ind...
Atrium Therapeutics earns $15M milestone payment from Bristol Myers
Atrium Therapeutics (RNA) announced it has earned another $15M milestone payment from Bristol Myers Squibb (BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology...
Atrium Therapeutics reports Q2 EPS ($1.18) vs (75c) last year
Reports Q2 revenue $3M vs $3.85M last year. “Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis – Atrium’s first Phase…
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- ...
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutic...
Atrium Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Atrium Therapeutics (RNA) with a Buy rating and $25 price target The company is “mispriced” ahead of the first human biopsy data that may prove…
Atrium Therapeutics announces FDA clearance of ATR 1072 IND application
Atrium Therapeutics (RNA) announced that the FDA has cleared its investigational new drug, or IND, application allowing the company to move forward with its Corventis Phase 1/2 clinical trial designed...
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
-- ATR 1072 is the company's first precision cardiology program to enter the clinic -- -- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential ...
Atrium Therapeutics Transcript: Transcript
Accelerated approval pathway for FSHD is now open, with Delvotax showing consistent improvements in muscle function, mobility, and quality of life in the Fortitude study. The CDUX biomarker is validated as a surrogate endpoint, and both pivotal and confirmatory phase III studies are underway, targeting broad patient benefit.
Atrium Therapeutics Transcript: Transcript
The acquisition expands the neuromuscular and RNA therapy portfolio, adding three late-stage assets with multibillion-dollar potential and strong regulatory designations. The $12B deal is expected to boost growth into the 2030s, with integration leveraging existing rare disease infrastructure.
Atrium Therapeutics Transcript: Transcript
Three late-stage clinical programs are advancing toward BLA filings, with Del-zota for DMD44 expected to launch in 2026 and additional filings for myotonic dystrophy and FSHD in 2026. Key data readouts and global commercial preparations are underway, supported by strong patient engagement and a robust cash position.
Atrium Therapeutics Transcript: Transcript
Atrium Therapeutics Transcript: Transcript
Consistent positive data across neuromuscular programs in 2024 support registrational trials and expansion into precision cardiology. Key clinical milestones are on track, with major data and regulatory updates expected in 2025, alongside a commercial buildout.
Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target Atrium’s RNA delivery programs using antibody-oligonucleotide conjugates for PRKAG2 syn...
Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target
Atrium Therapeutics Transcript: Transcript
Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform
Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target calling the company “an interesting preclinical-stage opportunity in precision cardiology.” While...
Atrium Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target
Atrium Therapeutics Reports First Quarter 2026 Financial Results
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by develo...